-
Abe T, Barber GN, 2014: Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-kappaB activation through TBK1[J]. J Virol, 88, 5328-5341. doi: 10.1128/JVI.00037-14
-
Aubert M, Krantz EM, Jerome KR, 2006: Herpes simplex virus genes Us3, Us5, and Us12 differentially regulate cytotoxic T lymphocyte-induced cytotoxicity[J]. Viral Immunol, 19, 391-408. doi: 10.1089/vim.2006.19.391
-
Awasthi S, Lubinski JM, Eisenberg RJ, Cohen GH, Friedman HM, 2008: An HSV-1 gD mutant virus as an entry-impaired live virus vaccine[J]. Vaccine, 26, 1195-1203. doi: 10.1016/j.vaccine.2007.12.032
-
Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Morrow RL, Ewell MG, Stokes-Riner A, Dubin G, Heineman TC, Schulte JM, Deal CD, 2012: Efficacy results of a trial of a herpes simplex vaccine[J]. N Engl J Med, 366, 34-43. doi: 10.1056/NEJMoa1103151
-
Cartier A, Komai T, Masucci MG, 2003: The Us3 protein kinase of herpes simplex virus 1 blocks apoptosis and induces phosporylation of the Bcl-2 family member Bad[J]. Exp Cell Res, 291, 242-250. doi: 10.1016/S0014-4827(03)00375-6
-
Cattamanchi A, Posavad CM, Wald A, Baine Y, Moses J, Higgins TJ, Ginsberg R, Ciccarelli R, Corey L, Koelle DM, 2008: Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system[J]. Clin Vaccine Immunol, 15, 1638-1643. doi: 10.1128/CVI.00167-08
-
Coleman JL, Shukla D, 2013: Recent advances in vaccine development for herpes simplex virus types I and II[J]. Hum Vaccin Immunother, 9, 729-735. doi: 10.4161/hv.23289
-
Fan S, Xu X, Liao Y, Wang Y, Wang J, Feng M, Wang L, Zhang Y, He Z, Yang F, Fraser NW, Li Q, 2018: Attenuated phenotype and immunogenic characteristics of a mutated herpes simplex virus 1 strain in the rhesus macaque[J]. Viruses, 10, E234-. doi: 10.3390/v10050234
-
Farooq AV, Shukla D, 2012: Herpes simplex epithelial and stromal keratitis: an epidemiologic update[J]. Surv Ophthalmol, 57, 448-462. doi: 10.1016/j.survophthal.2012.01.005
-
Galvan V, Roizman B, 1998: Herpes simplex virus 1 induces and blocks apoptosis at multiple steps during infection and protects cells from exogenous inducers in a cell-type-dependent manner[J]. Proc Natl Acad Sci USA, 95, 3931-3936. doi: 10.1073/pnas.95.7.3931
-
Imai T, Koyanagi N, Ogawa R, Shindo K, Suenaga T, Sato A, Arii J, Kato A, Kiyono H, Arase H, Kawaguchi Y, 2013: Us3 kinase encoded by herpes simplex virus 1 mediates downregulation of cell surface major histocompatibility complex class I and evasion of CD8+ T cells[J]. PLoS ONE, 8, e72050-. doi: 10.1371/journal.pone.0072050
-
Jerome KR, Chen Z, Lang R, Torres MR, Hofmeister J, Smith S, Fox R, Froelich CJ, Corey L, 2001: HSV and glycoprotein J inhibit caspase activation and apoptosis induced by granzyme B or Fas[J]. J Immunol, 167, 3928-3935. doi: 10.4049/jimmunol.167.7.3928
-
Johnston C, Gottlieb SL, Wald A, 2016: Status of vaccine research and development of vaccines for herpes simplex virus[J]. Vaccine, 34, 2948-2952. doi: 10.1016/j.vaccine.2015.12.076
-
Kessler HH, Muhlbauer G, Rinner B, Stelzl E, Berger A, Dorr HW, Santner B, Marth E, Rabenau H, 2000: Detection of herpes simplex virus DNA by real-time PCR[J]. J Clin Microbiol, 38, 2638-2642.
-
Khanna KM, Bonneau RH, Kinchington PR, Hendricks RL, 2003: Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia[J]. Immunity, 18, 593-603. doi: 10.1016/S1074-7613(03)00112-2
-
Knickelbein JE, Khanna KM, Yee MB, Baty CJ, Kinchington PR, Hendricks RL, 2008: Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency[J]. Science, 322, 268-271. doi: 10.1126/science.1164164
-
Koyanagi N, Imai T, Shindo K, Sato A, Fujii W, Ichinohe T, Takemura N, Kakuta S, Uematsu S, Kiyono H, Maruzuru Y, Arii J, Kato A, Kawaguchi Y, 2017: Herpes simplex virus-1 evasion of CD8 +T cell accumulation contributes to viral encephalitis[J]. J Clin Invest, 127, 3784-3795. doi: 10.1172/JCI92931
-
Kukhanova MK, Korovina AN, Kochetkov SN, 2014: Human herpes simplex virus: life cycle and development of inhibitors[J]. Biochemistry (Mosc), 79, 1635-1652. doi: 10.1134/S0006297914130124
-
Lan K, Luo MH, 2017: Herpesviruses: epidemiology, pathogenesis, and interventions[J]. Virol Sin, 32, 347-348. doi: 10.1007/s12250-017-4108-2
-
Leopardi R, Van Sant C, Roizman B, 1997: The herpes simplex virus 1 protein kinase US3 is required for protection from apoptosis induced by the virus[J]. Proc Natl Acad Sci USA, 94, 7891-7896. doi: 10.1073/pnas.94.15.7891
-
Mori I, Goshima F, Watanabe D, Ito H, Koide N, Yoshida T, Liu B, Kimura Y, Yokochi T, Nishiyama Y, 2006: Herpes simplex virus US3 protein kinase regulates virus-induced apoptosis in olfactory and vomeronasal chemosensory neurons in vivo[J]. Microbes Infect, 8, 1806-1812. doi: 10.1016/j.micinf.2006.02.018
-
Mostafa HH, Thompson TW, Konen AJ, Haenchen SD, Hilliard JG, Macdonald SJ, Morrison LA, Davido DJ, 2018: Herpes simplex virus 1 mutant with point mutations in UL39 is impaired for acute viral replication in mice, establishment of latency, and explant-induced reactivation[J]. J Virol, 92, e01654-17.
-
Orvedahl A, Alexander D, Talloczy Z, Sun Q, Wei Y, Zhang W, Burns D, Leib DA, Levine B, 2007: HSV-1 ICP34[J]. 5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe, 1, 23-35.
-
Paludan SR, Bowie AG, Horan KA, Fitzgerald KA, 2011: Recognition of herpesviruses by the innate immune system[J]. Nat Rev Immunol, 11, 143-154. doi: 10.1038/nri2937
-
Rajcani J, Banati F, Szenthe K, Szathmary S, 2018: The potential of currently unavailable herpes virus vaccines[J]. Expert Rev Vaccines, 17, 239-248. doi: 10.1080/14760584.2018.1425620
-
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F, 2013: Genome engineering using the CRISPR-Cas9 system[J]. Nat Protoc, 8, 2281-2308. doi: 10.1038/nprot.2013.143
-
Royer DJ, Gurung HR, Jinkins JK, Geltz JJ, Wu JL, Halford WP, Carr DJJ, 2016: A highly efficacious herpes simplex virus 1 vaccine blocks viral pathogenesis and prevents corneal immunopathology via humoral immunity[J]. J Virol, 90, 5514-5529. doi: 10.1128/JVI.00517-16
-
Salvucci A, Bonneau RH, Tevethia SS, 1995: Polymorphism within the herpes simplex virus (HSV) ribonucleotide reductase large subunit (ICP6) confers type specificity for recognition by HSV type 1-specific cytotoxic T lymphocytes[J]. J Virol, 69, 1122-1131.
-
St Leger AJ, Peters B, Sidney J, Sette A, Hendricks RL, 2011: Defining the herpes simplex virus-specific CD8+ T cell repertoire in C57BL/6 mice[J]. J Immunol, 186, 3927-3933. doi: 10.4049/jimmunol.1003735
-
Stanfield B, Kousoulas KG, 2015: Herpes simplex vaccines: prospects of live-attenuated HSV vaccines to combat genital and ocular infections[J]. Curr Clin Microbiol Rep, 2, 125-136. doi: 10.1007/s40588-015-0020-4
-
Wakim LM, Jones CM, Gebhardt T, Preston CM, Carbone FR, 2008: CD8(+) T-cell attenuation of cutaneous herpes simplex virus infection reduces the average viral copy number of the ensuing latent infection[J]. Immunol Cell Biol, 86, 666-675. doi: 10.1038/icb.2008.47
-
Wallace ME, Keating R, Heath WR, Carbone FR, 1999: The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant[J]. J Virol, 73, 7619-7626.
-
Wang S, Wang K, Lin R, Zheng C, 2013: Herpes simplex virus 1 serine/threonine kinase US3 hyperphosphorylates IRF3 and inhibits beta interferon production[J]. J Virol, 87, 12814-12827. doi: 10.1128/JVI.02355-13
-
Wang K, Ni L, Wang S, Zheng C, 2014: Herpes simplex virus 1 protein kinase US3 hyperphosphorylates p65/RelA and dampens NF-κB activation[J]. J Virol, 88, 7941-7951. doi: 10.1128/JVI.03394-13
-
Watson ZL, Washington SD, Phelan DM, Lewin AS, Tuli SS, Schultz GS, Neumann DM, Bloom DC, 2018: in vivo knockdown of the herpes simplex virus 1 latency-associated transcript reduces reactivation from latency[J]. J Virol, 92, e00812-18.
-
Wilcox DR, Longnecker R, 2016: The herpes simplex virus neurovirulence factor gamma34.5: revealing virus-host interactions[J]. PLoS Pathog, 12, e1005449-. doi: 10.1371/journal.ppat.1005449
-
Xu X, Fan S, Zhou J, Zhang Y, Che Y, Cai H, Wang L, Guo L, Liu L, Li Q, 2016: The mutated tegument protein UL7 attenuates the virulence of herpes simplex virus 1 by reducing the modulation of α-4 gene transcription[J]. Virol J, 13, 152-. doi: 10.1186/s12985-016-0600-9
-
Xu X, Fan S, Wang X, Hu Y, Feng M, Wang L, Zhang Y, Liao Y, Zhang X, Li Q, 2017a: Analysis of the protective immunity induced by herpes simplex virus 1 strain M3 with an attenuated phenotype due to mutations in the viral ul7, ul41, and LAT genes[J]. Front Microbiol, 8, 1958-. doi: 10.3389/fmicb.2017.01958
-
Xu X, Guo Y, Fan S, Cui P, Feng M, Wang L, Zhang Y, Liao Y, Zhang X, Li Q, 2017b: Attenuated phenotypes and analysis of a herpes simplex virus 1 strain with partial deletion of the UL7, UL41 and LAT genes[J]. Virol Sin, 32, 404-414. doi: 10.1007/s12250-017-3947-1
-
Yu X, He S, 2016: The interplay between human herpes simplex virus infection and the apoptosis and necroptosis cell death pathways[J]. Virol J, 13, 77-. doi: 10.1186/s12985-016-0528-0
-
Zheng C, 2018: Evasion of cytosolic DNA-stimulated innate immune responses by herpes simplex virus 1[J]. J Virol, 92, e00099-17.